In essence, this study suggests that PTX3, a potential biomarker for distinguishing prostate cancer from BPH, promotes tumor progression by inhibiting the activation of the terminal complement pathway through increased CD59 expression (75). Here, PTX3 is linked to Familial prostate cancer.